iA Global Asset Management Inc. Has $4.71 Million Stock Holdings in Exact Sciences Corporation $EXAS

iA Global Asset Management Inc. boosted its position in shares of Exact Sciences Corporation (NASDAQ:EXAS) by 9.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 85,999 shares of the medical research company’s stock after acquiring an additional 7,500 shares during the period. iA Global Asset Management Inc.’s holdings in Exact Sciences were worth $4,705,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the company. True Wealth Design LLC grew its holdings in shares of Exact Sciences by 951.8% during the 2nd quarter. True Wealth Design LLC now owns 589 shares of the medical research company’s stock worth $31,000 after purchasing an additional 533 shares in the last quarter. Country Trust Bank acquired a new position in shares of Exact Sciences in the second quarter valued at $32,000. Bessemer Group Inc. lifted its position in Exact Sciences by 1,980.6% in the second quarter. Bessemer Group Inc. now owns 645 shares of the medical research company’s stock worth $34,000 after purchasing an additional 614 shares during the period. Parallel Advisors LLC boosted its stake in Exact Sciences by 120.1% during the second quarter. Parallel Advisors LLC now owns 799 shares of the medical research company’s stock worth $42,000 after buying an additional 436 shares in the last quarter. Finally, Quent Capital LLC acquired a new stake in Exact Sciences during the third quarter worth $48,000. Institutional investors and hedge funds own 88.82% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on EXAS shares. Benchmark cut shares of Exact Sciences from a “buy” rating to a “hold” rating in a research note on Monday, November 24th. Leerink Partners cut shares of Exact Sciences from a “strong-buy” rating to a “hold” rating in a research note on Thursday, November 20th. BTIG Research lowered shares of Exact Sciences from a “buy” rating to a “neutral” rating in a research report on Thursday, November 20th. Robert W. Baird set a $105.00 price target on shares of Exact Sciences in a research note on Thursday, November 20th. Finally, Guggenheim downgraded Exact Sciences from a “buy” rating to a “neutral” rating in a report on Thursday, November 20th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, twenty have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Exact Sciences has a consensus rating of “Hold” and an average target price of $89.56.

Exact Sciences Trading Down 0.1%

Shares of EXAS stock opened at $102.26 on Friday. The company has a market capitalization of $19.51 billion, a P/E ratio of -19.22, a P/E/G ratio of 2.42 and a beta of 1.40. Exact Sciences Corporation has a 12-month low of $38.81 and a 12-month high of $102.66. The company has a quick ratio of 2.44, a current ratio of 2.72 and a debt-to-equity ratio of 0.93. The firm has a 50-day moving average price of $100.01 and a 200 day moving average price of $70.20.

Exact Sciences (NASDAQ:EXAS) last issued its quarterly earnings data on Monday, November 3rd. The medical research company reported $0.24 earnings per share for the quarter, topping the consensus estimate of $0.13 by $0.11. Exact Sciences had a negative net margin of 32.01% and a positive return on equity of 1.67%. The firm had revenue of $850.74 million for the quarter, compared to analysts’ expectations of $810.42 million. During the same period in the prior year, the firm earned ($0.21) earnings per share. The company’s quarterly revenue was up 20.0% compared to the same quarter last year. Research analysts forecast that Exact Sciences Corporation will post -0.58 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, EVP Jacob A. Orville sold 5,000 shares of the firm’s stock in a transaction on Wednesday, November 19th. The stock was sold at an average price of $75.00, for a total transaction of $375,000.00. Following the completion of the sale, the executive vice president directly owned 23,237 shares of the company’s stock, valued at $1,742,775. This trade represents a 17.71% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Brian Baranick sold 2,858 shares of Exact Sciences stock in a transaction on Tuesday, November 4th. The shares were sold at an average price of $70.08, for a total value of $200,288.64. Following the completion of the transaction, the executive vice president owned 22,368 shares of the company’s stock, valued at approximately $1,567,549.44. The trade was a 11.33% decrease in their position. The SEC filing for this sale provides additional information. 1.20% of the stock is owned by corporate insiders.

Exact Sciences Profile

Exact Sciences Corporation is a molecular diagnostics company headquartered in Madison, Wisconsin, dedicated to the early detection and prevention of cancer. The company’s flagship product, Cologuard®, is a noninvasive, stool-based DNA screening test for colorectal cancer that was developed in collaboration with the Mayo Clinic. By combining DNA mutation analysis with hemoglobin detection, Cologuard aims to improve screening adherence and identify cancers and precancerous lesions in average-risk adults.

Since its founding in 1995, Exact Sciences has expanded its portfolio through strategic acquisitions and internal research and development.